<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828202</url>
  </required_header>
  <id_info>
    <org_study_id>ID-RCB 2015-A00138-41</org_study_id>
    <secondary_id>2011-244</secondary_id>
    <nct_id>NCT02828202</nct_id>
  </id_info>
  <brief_title>Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients</brief_title>
  <acronym>MelBase</acronym>
  <official_title>Constitution of a National Cohort of Patients With Metastatic Melanoma Stage IV or Unresectable Stage III With the Objective of Setting up a Epidemiological Monitoring and a Clinico-biological Database, MELBASE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevention of melanoma can be efficient but mortality remains unchanged and 15 to 20% of
      patients still die from melanoma. Indeed metastatic melanoma is a heterogeneous highly and
      multiple mutations driven cancer. Significant survival benefit was demonstrated since 2011
      with anti-CTLA4, programmed death-1 (anti PD1) antibodies, B-Raf proto-oncogene,
      serine/threonine kinase (BRAF) and MAP-ERK kinase (MEK) inhibitors. Future improvement of
      advanced melanoma prognosis will rely on clinico-epidemiological studies and on biological
      studies aiming to validate and identify new prognostic and predictive factors based upon
      clinico-epidemiological and histological data, genomic host and tumor alterations, tumor
      microenvironment characteristics, individual immunological profile and functional imaging. In
      the context of marketing of costly innovative molecules prospective collection of economic
      data on treatment and toxicity are required. Large biobanks collecting data from cohorts of
      advanced melanoma are mandatory for such projects.

      MELBASE is a French prospective national cohort enrolling advanced melanoma patients whose
      objectives are :

        -  To provide an annual instrument panel with a descriptive and correlative analysis of
           patients with advanced melanoma in France including epidemiological, clinical and
           biological socio-economic characteristics

        -  to validate and identify new clinical, epidemiological, and biological prognostic
           factors such as genomic host and tumor alterations, tumor microenvironment
           characteristics, individual immunological profile in advanced melanoma.

        -  to evaluate the risk-benefit, the impact on treatment on patient quality of life, the
           management cost of patients treated with the validated and future treatments of
           metastatic melanoma. The project also aims to define predictive biomarkers of response
           and toxicity including pharmacogenetics and tumor genetics alterations, tumor
           microenvironment characteristics, individual immunological profile.

      Patients with unresectable stage III or stage IV melanoma will be enrolled prospectively for
      1 year with a 5 years follow-up (a total of 2000 patients will be enrolled) from 26 French
      centers A database of clinical monitoring of metastatic patients will be established and
      associated with a virtual tumor bank. This national database will be issued from the use of
      biological, clinical and imaging databases already available in the centers and optimized for
      this project; this database will also results from the interaction with the French national
      cancer institute (INCa) genotyping platform.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melanoma is the first cancer in terms of increasing frequency in France. Prevention can be
      efficient in detecting melanoma with good prognosis but mortality remains unchanged and 15 to
      20% of patients still die from melanoma. Indeed metastatic melanoma is a heterogeneous highly
      and multiple mutations driven cancer which is highly resistant to conventional treatments.
      Significant survival benefit was demonstrated since 2011 with anti-CTLA4 and anti PD1
      antibodies and BRAF and MEK inhibitors .Future improvement of advanced melanoma prognosis
      will rely on clinico-epidemiological studies and on biological studies aiming to validate and
      identify new prognostic and predictive factors based upon clinico-epidemiological and
      histological data, genomic host and tumor alterations, tumor microenvironment
      characteristics, individual immunological profile and functional imaging. In the context of
      marketing of costly innovative molecules in this indication, an assessment of resource
      consumption is required, with prospective collection of economic data on treatment and
      toxicity. Large biobanks collecting data from cohorts of advanced melanoma are mandatory for
      such projects.

      The &quot;Groupe Multidisciplinaire Français du Mélanome cutané&quot; (GMFmel) group plans to build a
      prospective cohort enrolling advanced melanoma patients, MELBASE. MELBASE is a French
      national multidisciplinary project whose objectives are :

        -  To provide an annual instrument panel with a descriptive and correlative analysis of
           patients with advanced melanoma in France including epidemiological, clinical and
           biological socio-economic characteristics

        -  to validate and identify new clinical, epidemiological, and biological prognostic
           factors such as genomic host and tumor alterations, tumor microenvironment
           characteristics, individual immunological profile in advanced melanoma.

        -  to evaluate the risk-benefit, he impact on treatment on patient quality of life, the
           management cost of patients treated with the validated and future treatments of
           metastatic melanoma. If possible, cost-effectiveness ratios wil be calculated either in
           all treated patients or in selected populations of patients (based on clinical or
           biological criteria, like biomarkers), in order to identify the populations in which
           these new therapeutics will be the more cost-effective. The project also aims to define
           predictive biomarkers of response and toxicity including pharmacogenetics and tumor
           genetics alterations, tumor microenvironment characteristics, individual immunological
           profile.

      Patients with unresectable stage III or stage IV melanoma will be enrolled prospectively for
      6 years with a 5 years follow-up (a total of 2000 patients will be enrolled) from 26 French
      centers.

      A database of clinical monitoring of metastatic patients will be established and associated
      with a virtual tumor bank. The database will be issued from the use of biological, clinical
      and imaging databases already available in the centers and optimized for this project; this
      database will also results from the interaction with the INCa genotyping platform. The
      information collected in MELBASE will include clinical constitutional factors, factors linked
      to primary melanoma, factors linked to previous lymph node involvement, tumor kinetics
      informations, &quot;American Joint Committee on Cancer&quot; (AJCC) stage at inclusion and after
      various therapeutic intervention, serological markers, metastatic tumor genotyping (one or
      more sites, one or more time points), therapeutic interventions (medical, surgical,
      radiotherapy and palliative strategies) with evaluation of response, tolerance, medical
      direct costs, impact on quality of life, psycho-socio-economic variables including a specific
      a specific questionnaire, date of death, date of latest news.

      MELBASE will comprise a virtual Tumor bank collecting samples from the same unresectable
      stage III and stage IV patients enrolled in the study. These samples will be available in the
      Biological Resource Centers (BRC) of each participating center and will consist of the
      primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and
      frozen) from at least 1 site at inclusion and during evolution, particularly before treatment
      modification if clinically required, DNA from peripheral blood mononuclear cells, plasma
      sampled at inclusion, every 6 months and at each new treatment line during 3 years.

      The computer data processing will therefore ensure the role of a data warehouse to generate
      clinico-epidemiological reports and analysis and that of a virtual catalog of biological
      material. MELBASE project will be consistent with the ethical chart of the hospital tumor
      banks published by Inca and will be managed by a chart ensuring each participating center
      management autonomy and availability of the data put into the database and made available. A
      multidisciplinary scientific advisory board will identify research priorities based on
      clinical practice and scientific knowledge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>With a Kaplan-Meier curve analysis and Cox model</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>With a Kaplan-Meier curve analysis and Cox model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>5 years</time_frame>
    <description>Determined by tumor assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature and incidence of Treatment-Emergent Adverse Events (Safety)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluated with CTCAE v4.0</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological</intervention_name>
    <description>DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tissular</intervention_name>
    <description>Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life</intervention_name>
    <description>Specific questionnaires (FACT-M, EUROQUOL, MMAS8) at inclusion, every 3 months and before each new systemic therapy.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and
      frozen) from at least 1 site at inclusion and during evolution, particularly before treatment
      modification if clinically required, DNA and RNA from peripheral blood mononuclear cells,
      plasma, serum, peripheral blood mononuclear cells sampled at inclusion, every 6 months and
      before each new systemic therapy during 3 years.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With Metastatic Melanoma Stage IV or Unresectable Stage III.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with an advanced melanoma, confirmed by histological exam.

          -  Primitive unresectable stage 3 or 4 melanoma.

          -  Aged &gt; 18 years.

          -  Naïve of systemic treatment for an unresectable stage 3 or 4 melanoma, except adjuvant
             treatment.

          -  Whose metastatic tumoral material can be collected by the Biological Resource Centers
             (optional criteria).

          -  Consenting to participate (signed informed consent).

        Exclusion Criteria:

          -  Patients refusal.

          -  Choroid melanoma.

          -  Resectable stage 1, 2 or 3 melanoma.

          -  Patients under guardianship and under trusteeship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celeste Lebbe, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris (AP-HP), Hopital Saint-Louis, centre d'oncodermatologie, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brigitte Dreno, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celeste Lebbe, MD, PhD</last_name>
    <phone>+33142494679</phone>
    <email>celeste.lebbe@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clara Allayous, PhD</last_name>
    <phone>+33142499392</phone>
    <email>clara.allayous@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Lok, MD, PhD</last_name>
      <email>lok.catherine@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Lok, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe Arnault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Duverlie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves-Edouard Herpe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri Sevestre, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie De Quatrebarbes, MD, PhD</last_name>
      <email>jdequatrebarbes@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Julie De Quatrebarbes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Claire Bing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benedicte Hars, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Aubin, MD, PhD</last_name>
      <email>francois.aubin@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>François Aubin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Severine Valmary-Degano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Avicennes</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eve Maubec, MD, PhD</last_name>
      <email>eve.maubec@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Eve Maubec, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerome Bohelay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentine Heidelberger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coralie Zumelzu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Schischmanoff, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine Martin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Hôpital Haut Levêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Dutriaux, MD, PhD</last_name>
      <email>caroline.dutriaux@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline Dutriaux, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sorilla Prey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>H Conte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie Gerard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe Merlio, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatrice Vergier, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Dubus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Saiag, MD, PhD</last_name>
      <email>philippe.saiag@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Saiag, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Longvert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Lipowicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amelie Gantzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daphne Bosset, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Florence De Maleissye, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adeline Finet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Astrid Blom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre Rabes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François Emile, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Legoupil, MD</last_name>
      <email>delphine.legoupil@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine Legoupil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Misery, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Abasq, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie Brenaut, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale Marcorelles, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Cecile Nicot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Dalac, MD, PhD</last_name>
      <email>sophie.dalac@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Dalac, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Vabres, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne Collet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geraldine Jeudy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Helene Aubriot Lorton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tony Petrella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertille Bonniaud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain Bonnin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Therese Leccia, MD, PhD</last_name>
      <email>mtleccia@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Therese Leccia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Lorimier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Pinel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Mortier, MD, PhD</last_name>
      <email>laurent.mortier@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Mortier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Greliak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Deplanque, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Christine Copin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eve-Marie Neidhardt, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Eve-Marie Neidhardt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Dalle, PD, PhD</last_name>
      <email>stephane.dalle@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Stephane Dalle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Thomas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona Amini-Adle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastien Debarbieux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Traverse-Glehen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Fabien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte Balme, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauriane Depaepe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques Grob, MD, PhD</last_name>
      <email>jean-jacques.grob@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Jacques Grob, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Gaudy, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine Monestier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie Hesse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nausicaa Malissen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Figarella-Branger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Guillot, MD, PhD</last_name>
      <email>b-guillot@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard Guillot, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline Montet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie Bertrand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anouck Lamoureux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Costes-Martineau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie Dupuy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Rigau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Granel-Brocard, MD</last_name>
      <email>f.granel-brocard@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Granel-Brocard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Charbit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Michel Vignaud, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Dreno, MD, PhD</last_name>
      <email>brigitte.dreno@atlanmed.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Dreno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe Lacour, MD, PhD</last_name>
      <email>lacour@unice.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Lacour, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Bahadoran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Passeron, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri Montaudie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Le Duff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marine Cavalie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Picard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feriel Boukari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Hofman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronique Hofman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Butori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Emmanuel Stoebner, MD, PhD</last_name>
      <email>pierre.stoebner@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Emmanuel Stoebner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny Fichel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Lavabre-Bertrand, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Baptiste Gaillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Roger, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris (AP-HP), Hopital Saint-Louis, centre d'oncodermatologie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Lebbe, MD, PhD</last_name>
      <email>celeste.lebbe@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Celeste Lebbe, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Roux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barouyr Baroudjian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline Laly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Delyon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Herms, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Vitoux, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Chevrier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamad Hinedi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Janin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime Batistella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Descamps, MD, PhD</last_name>
      <email>vincent.descamps@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Descamps, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatrice Crickx, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Fite, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Picard-Dahan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Vuong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Brunet-Possenti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Kottler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Tubiana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Couvelard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lydia Deschamps, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Françoise Avril, MD, PhD</last_name>
      <email>marie-francoise.avril@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Françoise Avril, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Dupuy, MD, PhD</last_name>
      <email>alain.dupuy@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Alain Dupuy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Dominique Galibert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Dinulescu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecile Chabbert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Droitcourt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri Adamski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Turlin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lesimple, MD, PhD</last_name>
      <email>t.lesimple@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Lesimple, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Pracht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Turlin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Meyer, MD, PhD</last_name>
      <email>meyer.n@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Meyer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Thellier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianne Thomas-Pfaab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecile Pages Laurent, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Brousset, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Robert, MD, PhD</last_name>
      <email>caroline.robert@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline Robert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Skin</keyword>
  <keyword>Biobank</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

